Purespring Therapeutics raises £80/$105 million in a Series B …

London – 9 October 2024 – Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised …

CouponFollow Extension

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

London – 9 October 2024 – Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised …

purespringtx.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

London – 9 October 2024 - Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised …

yahoo.com

£80
OFF

Purespring Therapeutics Raises £80 Million In A Series B Financing

6 days from now

Oct 10, 2024 · Purespring raises £80 million in a Series B financing, with Syncona committing £19.9 million [1] as part of a leading syndicate of life science investors. Proceeds will be used …

pharmiweb.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

Oct 9, 2024 · Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised £80/$105 million …

icheme.org

£80
OFF

Purespring Therapeutics Series B Financing

6 days from now

9 October 2024 . Syncona Limited . Purespring Therapeutics raises £80 million in a Series B financing · Purespring raises £80 million in a Series B financing, with Syncona committing …

londonstockexchange.com

£80
OFF

Purespring Therapeutics Series B Financing – Company …

6 days from now

9 October 2024 Syncona Limited Purespring Therapeutics raises £80 million in a Series B financing · Purespring raises £80 million in a Series B financing, with Syncona committing …

ft.com

$105
OFF

Purespring Therapeutics Raises $105M In Series B Financing

6 days from now

October 9, 2024. Purespring Therapeutics, a London, UK-based gene therapy company focused on enhancing the treatment of kidney diseases, raised $105M in Series B funding. The round …

finsmes.com

£80
OFF

Purespring Therapeutics Secures £80 Million In Series B Funding

6 days from now

Oct 9, 2024 · Purespring Therapeutics has raised £80m in an oversubscribed Series B financing round. Syncona Ltd, a leading life science investor, committed £19.9m as part of a syndicate …

pharmatimes.com

$105
OFF

Purespring Bottles Up $105M Series B For Kidney Gene Therapy

6 days from now

Oct 9, 2024 · London-based biotech Purespring Therapeutics plans to bring their kidney-tweaking gene therapy to the clinic with the help of a new £80 million (about $105 million) pool of series …

fiercebiotech.com

$105
OFF

Purespring Therapeutics Raises £80M In Series B Round To Launch …

6 days from now

Oct 9, 2024 · NEW YORK – Purespring Therapeutics on Wednesday announced that it has raised £80 million ($105 million) in an oversubscribed Series B financing round, which it plans to use …

precisionmedicineonline.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In Series B …

6 days from now

London, 7 October, 2024 - Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised £80/$105 …

forbion.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

London – 9 October 2024 - Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised …

businessinsider.com

$105
OFF

Purespring Raises $105M To Advance Gene Therapy For Kidney Disease

6 days from now

Oct 9, 2024 · Jian Fan via Getty Images. Biotechnology company Purespring Therapeutics has raised about $105 million to fund its development of gene therapies for diseases of the kidney. …

biopharmadive.com

£80
OFF

Purespring Therapeutics Series B Financing - Sharecast.com

6 days from now

09 October 2024. Purespring Therapeutics raises £80 million in a Series B financing. · Purespring raises £80 million in a Series B financing, with Syncona committing £19.9 million[1] as part ...

sharecast.com

$105
OFF

Purespring Secures $105m To Start Phase I/II Trial Of IgAN Gene …

6 days from now

Oct 9, 2024 · Purespring secures $105m to start Phase I/II trial of IgAN gene therapy. Purespring Therapeutics has raised $105m in a Series B funding round which will help progress its lead …

clinicaltrialsarena.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

London – 9 October 2024 - Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised …

synconaltd.com

FAQs about Purespring Therapeutics raises £80/$105 million in a Series B … Coupon?

Does purespring therapeutics have a series B financing?

Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases Oversubscribed financing led by Sofinnova Partners in collaboration with Gilde Healthcare, Forbion, British Patient Capital and founding investor Syncona ...

Who is purespring Therapeutics?

London – 9 October 2024 - Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised £80/$105 million in a Series B financing. ...

Does purespring therapeutics have a kidney nephropathy program?

Biotechnology company Purespring Therapeutics has raised about $105 million to fund its development of gene therapies for diseases of the kidney. The Series B funding announced Wednesday was led by Sofinnova Partners and will support Purespring’s initiation of a Phase 1/2 study of its lead candidate for IgA nephropathy, or IgAN. ...

Will purespring bring kidney-tweaking gene therapy to the clinic?

London-based biotech Purespring Therapeutics plans to bring their kidney-tweaking gene therapy to the clinic with the help of a new £80 million (about $105 million) pool of series B cash. ...

What will purespring do with proceeds from a Phase I/II clinical trial?

Proceeds will be used to support Purespring’s pipeline including the initiation of a Phase I/II clinical trial for IgA Nephropathy (IgAN), a common, chronic kidney disease primarily affecting young adults. About one third of IgAN patients will go on to lose their kidney function within five years and require a kidney transplant or dialysis. ...

What is purespring & how does it work?

Purespring’s platform technology allows working copies of genes to be delivered with high efficiency and specificity to podocytes, opening up a new and highly differentiated modality for disease modifying treatments of a broad range of kidney diseases. ...